Senator Jim Molan diagnosed with cancer

·2-min read

Liberal Senator Jim Molan has been diagnosed with an aggressive form of cancer and is taking leave for further testing.

The 70-year-old politician announced on Monday he would take time away from the Senate to confirm his prognosis and commence treatment.

"Whilst the news has come as a shock, I have many reasons to be positive," Senator Molan said in a statement.

"I am receiving the best possible care from my clinicians, and have the love, support and prayers of my family."

The senator said his NSW electoral office will remain open and fully operational, and that his team will continue to work hard alongside his colleagues in the Morrison government.

Senator Molan is a former major general in the Australian army and said he had never been afraid to fight the battles that need fighting.

"This is no exception," he added.

Both sides of politics wished him well in his treatment and recovery, including Prime Minister Scott Morrison.

"We've worked together for over a decade now and you've always put your service above all else," Mr Morrison wrote on the senator's Facebook post.

"Even now, in sharing this news of your illness, your thoughts still turn to how you can continue to serve.

"You're an incredible person Jim and we will all be here to support you through this challenging time ahead."

Labor senators Penny Wong, Kristina Keneally and Katy Gallagher also reached out with messages of support.

"Very sorry to hear this news, Jim. Strength and best wishes to you and yours," tweeted Ms Wong, the party's upper house leader.

Senator Molan first entered parliament in 2017 when the High Court declared him the elected replacement for Fiona Nash, who was ruled ineligible because of her dual citizenship.

Placed fourth on the coalition's NSW Senate ticket, he was not re-elected at the 2019 federal election but returned to the upper house after filling a casual vacancy left by retired senator Arthur Sinodinos.

His term in the senate is not due to expire until mid-2022.